Are any biocompatible coatings capable of attenuating the deleterious effects of cardiopulmonary bypass?
Authors:
- 29 April 2013
- journal article
- research article
- Published by SAGE Publications in Perfusion
- Vol. 28 (5) , 433-439
Abstract
Background: Biocompatible circuits (BCC) are intended to decrease the activation of blood to the artificial cardiopulmonary bypass (CPB) surface. Typically, the coatings are made of various inert substances or molecules physiologically similar to endothelium. Thromboelastography (TEG) graphically represents clot formation, strength of clotting and fibrinolysis. TEG analysis was undertaken to determine if coagulation could be preserved by the BCC. Methods: Five different BCC were studied in clinical applications. These five coated circuits were then compared to an identical circuit where only the oxygenator was coated. A pre- and post-bypass TEG was done for comparison. Six well-studied parameters of TEG analysis were compared: R time, Angle, K, Maximum Amplitude (MA), LY30% and Clot Index (CI). Postoperative bleeding and transfusion requirements were compared to TEG results for comparison. Results: All postoperative TEG results were significantly different from preoperative parameters except LY30%. No BCC circuit was able to prevent the significant disruption of the observed TEG coagulation parameters R, K, angle, MA and CI. Of note, the postoperative TEG parameters resulting from the Control and Trillium™ groups – which had the same type of oxygenator – were practically identical. The oxygenator, which represents the largest surface area in the CPB circuit, is the single most important factor influencing coagulation. Conclusion: While not harmful, BCC are ineffective in preserving TEG coagulation parameters post CPB. Clinical findings support laboratory TEG results in that there were no differences in bleeding or transfusion requirements between groups.Keywords
This publication has 28 references indexed in Scilit:
- Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?Interactive CardioVascular and Thoracic Surgery, 2012
- Principles and Practice of Thromboelastography in Clinical Coagulation Management and Transfusion PracticeTransfusion Medicine Reviews, 2012
- Evaluation of blood components exposed to coated arterial filters in extracorporeal circuitsPerfusion, 2009
- Barrier Function of the Gut and Multiple Organ Dysfunction after Cardiac SurgeryJournal of International Medical Research, 2007
- Biocompatibility of Heparin-Coated Cardiopulmonary Bypass Circuits in Coronary Patients With Left Ventricular Dysfunction Is Superior to PMEA-Coated CircuitsJournal of Cardiac Surgery, 2006
- The Impact of Tissue Factor Pathway Inhibitor on Coagulation Kinetics Determined by ThrombelastographyAnesthesia & Analgesia, 2006
- Effect of biopassive and bioactive surface‐coatings on the hemocompatibility of membrane oxygenatorsJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2006
- Phosphorylcholine Coating of Bypass Systems Used for Young Infants Does Not Attenuate the Inflammatory ResponseThe Annals of Thoracic Surgery, 2006
- The Impact of Heparin‐coated Circuits on Hemodynamics During and After Cardiopulmonary BypassArtificial Organs, 2005
- Reducing the Post-Pump Syndrome by Using Heparin-Coated Circuits, Steroids, or AprotininThe Thoracic and Cardiovascular Surgeon, 1999